Publikasjoner

Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles.

Mosevoll KA, Hansen BA, Gundersen IM, Reikvam H, Bruserud Ø, Bruserud Ø, Wendelbo Ø.Metabolites. 2022 Dec 29;13(1):52. doi: 10.3390/metabo13010052.PMID: 36676977

Platelets for advanced drug delivery in cancer.

Cacic D, Hervig T, Reikvam H.Expert Opin Drug Deliv. 2023 May;20(5):673-688. doi: 10.1080/17425247.2023.2217378. Epub 2023 May 26.PMID: 37212640 Review.

Better and safer allogeneic stem cell transplantation.

Reikvam H.Tidsskr Nor Laegeforen. 2023 Mar 13;143(4). doi: 10.4045/tidsskr.23.0083. Print 2023 Mar 14.PMID: 36919289

Tuberculosis-Associated Hemophagocytic Lymphohistiocytosis: A Review of Current Literature.

Fauchald T, Blomberg B, Reikvam H.J Clin Med. 2023 Aug 18;12(16):5366. doi: 10.3390/jcm12165366.PMID: 37629407 

Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia.

Reikvam H.Expert Rev Hematol. 2023 May;16(5):317-323. doi: 10.1080/17474086.2023.2202849. Epub 2023 Apr 17.PMID: 37066885

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.

Bruserud Ø, Reikvam H.Cancers (Basel). 2023 Jul 21;15(14):3711. doi: 10.3390/cancers15143711.PMID: 37509370 

The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients.

Bruserud Ø, Mosevoll KA, Bruserud Ø, Reikvam H, Wendelbo Ø.Cells. 2023 Mar 24;12(7):1003. doi: 10.3390/cells12071003.PMID: 37048076 

VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia.

Austestad J, Madland TM, Sandnes M, Haslerud TM, Benneche A, Reikvam H.Case Rep Hematol. 2023 Feb 25;2023:6551544. doi: 10.1155/2023/6551544. eCollection 2023.PMID: 36879894

Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis.

Reikvam H, Hetland G, Ezligini F, Dorsch K, Omert L, Dunham A, Almeland SK.Transfus Apher Sci. 2023 Jun 22:103755. doi: 10.1016/j.transci.2023.103755. Online ahead of print.PMID: 37423867

Treatment and Response Evaluation Challenges in a Pregnant Woman With B-Cell Lymphoblastic Leukemia and Li-Fraumeni Syndrome.

Erikstein BS, Ahmed AB, Forthun RB, Leh F, Gjertsen BT, Reikvam H.J Hematol. 2023 Apr;12(2):92-99. doi: 10.14740/jh1107. Epub 2023 Apr 30.PMID: 37187497

 GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2.

Lellahi SM, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, Kalland KH.Front Immunol. 2023 Jan 12;13:1058963. doi: 10.3389/fimmu.2022.1058963. eCollection 2022.PMID: 36713392

Pretransplant systemic metabolic profiles in allogeneic hematopoietic stem cell transplant recipients - identification of patient subsets with increased transplant-related mortality.

Reikvam H, Bruserud Ø, Hatfield KJ.Transplant Cell Ther. 2023 Jun;29(6):375.e1-375.e14. doi: 10.1016/j.jtct.2023.03.020. Epub 2023 Mar 24.PMID: 36966869

Systemic Metabolomic Profiles in Adult Patients with Bacterial Sepsis: Characterization of Patient Heterogeneity at the Time of Diagnosis.

Mosevoll KA, Hansen BA, Gundersen IM, Reikvam H, Bruserud Ø, Bruserud Ø, Wendelbo Ø.Biomolecules. 2023 Jan 24;13(2):223. doi: 10.3390/biom13020223.PMID: 36830594 

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.

Lilleskare S, Vorland M, Vo AK, Aarsand AK, Reikvam H.Scand J Clin Lab Invest. 2023 Feb;83(1):3-7. doi: 10.1080/00365513.2022.2150984. Epub 2022 Dec 7.PMID: 36476017

En mann i 40-årene med transfusjonskrevende anemi.

Sandnes M, Helgeland L, Johansen S, Reikvam H.Tidsskr Nor Laegeforen. 2023 Oct 23;143(15). doi: 10.4045/tidsskr.23.0022. Print 2023 Oct 24.PMID: 37874056

Liposomal drug formulations for treatment of hematological malignancies.

Limi DC, Reikvam H.Expert Opin Pharmacother. 2023 Oct 12:1-4. doi: 10.1080/14656566.2023.2269086. Online ahead of print.PMID: 37823599 

Platelets for advanced drug delivery in cancer.

Cacic D, Hervig T, Reikvam H.Expert Opin Drug Deliv. 2023 May;20(5):673-688. doi: 10.1080/17425247.2023.2217378. Epub 2023 May 26.PMID: 37212640 

Iron Status and Physical Performance in Athletes.

Solberg A, Reikvam H.Life (Basel). 2023 Oct 2;13(10):2007. doi: 10.3390/life13102007.PMID: 37895389

Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.

Gjelberg HK, Helgeland L, Liseth K, Micci F, Sandnes M, Russnes HG, Reikvam H.Curr Oncol. 2023 Nov 18;30(11):10007-10018. doi: 10.3390/curroncol30110727.PMID: 37999147 

Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity.

Bartaula-Brevik S, Leitch C, Hernandez-Valladares M, Aasebø E, Berven FS, Selheim F, Brenner AK, Rye KP, Hagen M, Reikvam H, McCormack E, Bruserud Ø, Tvedt THA.J Clin Med. 2023 Aug 25;12(17):5546. doi: 10.3390/jcm12175546.PMID: 37685612

PB1789: RAC1 INHIBITION IS FEASIBLE AND AFFECTS CELL MIGRATION IN A ZEBRAFISH LARVAE MODEL OF AML, INVESTIGATED USING A SOFTWARE TOOL FOR SINGLE-CELL VISUALIZATION

Anette Lodvir Hemsing, Jan-Lukas Førde, Kristin Paulsen Rye, Håkon Reikvam, Lars Herfindal

Hemasphere. 2023 Aug; 7(Suppl ): e9915813. Published online 2023 Aug 8. doi: 10.1097/01.HS9.0000974012.99158.13

PMCID: PMC10430263

5612976 FIRST ADMINISTRATION OF HYPOXIC BLOOD IN A TRANSFUSION-DEPENDENT PATIENT

H. Reikvam, G. Hetland, F. Ezligini, K. Dorsch, A. Dunham, L. Omert, S. Almeland

Hemasphere. 2023 Apr; 7(Suppl ): 41. Published online 2023 Apr 10. doi: 10.1097/01.HS9.0000928440.72522.5d

PMCID: PMC10112628

[Leukaemia cutis].

Holmemo HD, Reikvam H.Tidsskr Nor Laegeforen. 2021 Dec 22;141(1). doi: 10.4045/tidsskr.21.0695. Print 2022 Jan 11. PMID: 35026091

Eksamensformer i de norske medisinstudiene.

Raaheim OF, Raaheim DF, Reikvam H, Kvernenes M.Tidsskr Nor Laegeforen. 2022 Aug 12;142(11). doi: 10.4045/tidsskr.22.0337. Print 2022 Aug 16. PMID: 35997188

[When blood flows slowly].

Sandnes M, Reikvam H.Tidsskr Nor Laegeforen. 2022 Jun 7;142(9). doi: 10.4045/tidsskr.22.0026. Print 2022 Jun 14 PMID: 3569955

Lymphoplasmacytic variant of multiple myeloma.

Johansen S, Gjelberg HK, Reikvam H.EJHaem. 2022 Apr 8;3(2):563-564. doi: 10.1002/jha2.437. eCollection 2022 May PMID: 35846062

Thrombosis and thrombocytopenia after HPV vaccination.

Johansen S, Laegreid IJ, Ernstsen SL, Azrakhsh NA, Kittang AO, Lindås R, Gjertsen BT, Vetti N, Mørtberg TV, Sørvoll IH, Holme PA, Ahlen MT, Reikvam H.J Thromb Haemost. 2022 Mar;20(3):700-704. doi: 10.1111/jth.15604. Epub 2021 Dec 7. PMID: 34817130

Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia.

Reikvam H, Hemsing AL, Hernandez-Valladares M, Birkeland E.Expert Rev Proteomics. 2022 Feb;19(2):73-76. doi: 10.1080/14789450.2022.2067530. Epub 2022 Apr 22. PMID: 35436165

MicroRNA serum profiles and chronic graft-versus-host disease.

Reikvam H, Vo AK, Johansen S, Hemsing AL, Solheim MH, Mosevoll KA, Tvedt THA, Hatfield KJ.Blood Adv. 2022 Sep 27;6(18):5295-5306. doi: 10.1182/bloodadvances.2021005930. PMID: 35443023

Autologous hematopoietic stem cell grafts - moving away from a one-size-fits-all approach.

Melve GK, Sandnes M, Reikvam H.Expert Rev Hematol. 2022 Jan;15(1):1-4. doi: 10.1080/17474086.2022.2022470. Epub 2022 Jan 6. PMID: 34949139

Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future.

Rolsdorph LÅ, Mosevoll KA, Reikvam H.Expert Rev Hematol. 2022 Aug;15(8):667-670. doi: 10.1080/17474086.2022.2100341. Epub 2022 Jul 17. PMID: 35819263

Human papilloma virus vaccine and VITT antibody induction.

Kanack AJ, Laegreid IJ, Johansen S, Reikvam H, Ahlen MT, Padmanabhan A.Am J Hematol. 2022 Oct;97(10):E363-E364. doi: 10.1002/ajh.26659. Epub 2022 Aug 3. PMID: 35834243

Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches.

Vo AK, Hervig T, Reikvam H.Expert Opin Investig Drugs. 2022 Sep;31(9):881-884. doi: 10.1080/13543784.2022.2113055. PMID: 35975626

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.

Reikvam H, Hatfield KJ, Wendelbo Ø, Lindås R, Lassalle P, Bruserud Ø.Biomolecules. 2022 Mar 24;12(4):492. doi: 10.3390/biom12040492.

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.

Reikvam H, Hatfield KJ, Wendelbo Ø, Lindås R, Lassalle P, Bruserud Ø.Biomolecules. 2022 Mar 24;12(4):492. doi: 10.3390/biom12040492. PMID: 35454082

Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis.

Thunestvedt LMØ, Helgeland L, Bachmann IM, Karlsdottir Å, Haslerud TM, Reikvam H.Curr Oncol. 2022 Mar 23;29(4):2193-2198. doi: 10.3390/curroncol29040178. PMID: 35448152

Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation.

Johansen S, Kråkenes J, Vedeler CA, Storstein AM, Reikvam H.Case Reports Immunol. 2022 Sep 10;2022:4174755. doi: 10.1155/2022/4174755. eCollection 2022 PMID: 36124252

NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition.

Hemsing AL, Rye KP, Hatfield KJ, Reikvam H.Biomedicines. 2022 Aug 4;10(8):1881. doi: 10.3390/biomedicines10081881. PMID: 36009428

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.

Hatfield KJ, Bruserud Ø, Reikvam H.Cancers (Basel). 2022 Jun 13;14(12):2910. doi: 10.3390/cancers14122910. PMID: 35740576

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia.

Bruserud Ø, Reikvam H, Brenner AK.Molecules. 2022 Jan 23;27(3):735. doi: 10.3390/molecules27030735. PMID: 35163998

Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review.

Rolsdorph LÅ, Mosevoll KA, Helgeland L, Reikvam H.Front Med (Lausanne). 2022 Apr 19;9:819465. doi: 10.3389/fmed.2022.819465. eCollection 2022. PMID: 35514747

Musculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature.

Kvinge AD, Kvammen T, Miletic H, Bindoff LA, Reikvam H.Curr Oncol. 2022 Nov 3;29(11):8415-8430. doi: 10.3390/curroncol29110663. PMID: 36354723

Weight gain during treatment course of allogenic hematopoietic stem cell transplantation in patients with hematological malignancies affects treatment outcome.

Johansen S, Blomberg B, Vo AK, Wendelbo Ø, Reikvam H.Cytotherapy. 2022 Dec;24(12):1190-1194. doi: 10.1016/j.jcyt.2022.08.006. Epub 2022 Sep 20. PMID: 36151003

An Abrupt Transition to Digital Teaching-Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown.

Helland HK, Tylleskär T, Kvernenes M, Reikvam H.Healthcare (Basel). 2022 Jan 17;10(1):170. doi: 10.3390/healthcare10010170. PMID: 35052333

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.

Lilleskare S, Vorland M, Vo AK, Aarsand AK, Reikvam H.Scand J Clin Lab Invest. 2022 Dec 7:1-5. doi: 10.1080/00365513.2022.2150984. Online ahead of print.PMID: 36476017

Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition.

Brattås MK, Hemsing AL, Rye KP, Hatfield KJ, Reikvam H.Int J Mol Sci. 2022 Nov 25;23(23):14706. doi: 10.3390/ijms232314706.PMID: 36499034 

Ekstrem hypertriglyseridemi.

Vinnes EW, Hemsing AL.Tidsskr Nor Laegeforen. 2022 Nov 7;142(16). doi: 10.4045/tidsskr.22.0546. Print 2022 Nov 8.PMID: 36345642 

Thrombocytopaenia in the critically ill.

Bruserud Ø, Mosevoll KA, Kristoffersen E, Kvåle R, Reikvam H.Tidsskr Nor Laegeforen. 2021 Jan 11

Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach.

Reikvam H, Hemsing AL, Smith C.Expert Rev Anticancer Ther. 2021 Jan;21

Hyperferritinemia-A Clinical Overview.

Sandnes M, Ulvik RJ, Vorland M, Reikvam H.J Clin Med. 2021 May 7

Thrombosis and thrombocytopenia after HPV vaccination.

Johansen S, Laegreid IJ, Ernstsen SL, Azrakhsh NA, Kittang AO, Lindås R, Gjertsen BT, Vetti N, Mørtberg TV, Sørvoll IH, Holme PA, Ahlen MT, Reikvam H.J Thromb Haemost. 2021 Nov 24

Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review.

Wiese-Hansen H, Leh F, Lodvir Hemsing A, Reikvam H.J Clin Med. 2021 Apr

[A young woman with dyspnoea and proteinuria].

Hervig T, Tvedt THA, Knoop T, Sandnes M, Reikvam H.Tidsskr Nor Laegeforen. 2021 Nov  

Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences.

Tvedt THA, Vo AK, Bruserud Ø, Reikvam H.J Clin Med. 2021 Nov 6

Carbapenem-Resistant Enterobacteriaceae-Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies.

Storhaug KØ, Skutlaberg DH, Hansen BA, Reikvam H, Wendelbo Ø.Antibiotics (Basel). 2021 Mar 19

Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis.

Bruserud Ø, Tvedt THA, Ahmed AB, Vintermyr OK, Hervig T, Guttormsen AB, Reikvam H.Case Rep Crit Care. 2021 Mar 8

Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.

Bruserud Ø, Tsykunova G, Hernandez-Valladares M, Reikvam H, Tvedt THA.Pharmaceuticals (Basel). 2021 May 2

Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis.

Cacic D, Reikvam H, Nordgård O, Meyer P, Hervig T.Cancers (Basel). 2021 Apr 14

Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia.

Steinfeld PF, Knoop T, Trovik LH, Gjelberg HK, Haslerud TM, Reikvam H.Clin Pract. 2021 Jul 22

HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis.

Sandnes M, Vorland M, Ulvik RJ, Reikvam H.Genes (Basel). 2021 Jul 28

Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine.

Hatfield KJ, Grønningsaeter IS, Reikvam H.Curr Med Res Opin. 2021 Dec

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity.

Grønningsæter IS, Reikvam H, Aasebø E, Bartaula-Brevik S, Hernandez-Valladares M, Selheim F, Berven FS, Tvedt TH, Bruserud Ø, Hatfield KJ.J Pers Med. 2021 Aug

Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells.

Aasebø E, Brenner AK, Hernandez-Valladares M, Birkeland E, Mjaavatten O, Reikvam H, Selheim F, Berven FS, Bruserud Ø.Diseases. 2021 Oct 16

Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid.

Hernandez-Valladares M, Wangen R, Aasebø E, Reikvam H, Berven FS, Selheim F, Bruserud Ø.Cancers (Basel). 2021 Apr 29

p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.

Haaland I, Hjelle SM, Reikvam H, Sulen A, Ryningen A, McCormack E, Bruserud Ø, Gjertsen BT.Cells. 2021 Apr 7

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation.

Hemsing AL, Gjertsen BT, Spetalen S, Helgeland L, Reikvam H.SAGE Open Med Case Rep. 2021 Jan 22

  Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemia, Reikvam H, Johansen S, Koenecke C. Expert Review of Precision Medicine and Drug Development March 2021 6(2):1-5

Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation.   Reikvam H, Tvedt THA, Johansen, S, Aase Setran H, Havre RF. Transplantology 2020, 1, 102-110.

The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles.

Aasebø E, Berven FS, Hovland R, Døskeland SO, Bruserud Ø, Selheim F, Hernandez-Valladares M. Cancers (Basel). 2020 Jun 4;12(6):1466. doi: 10.3390/cancers12061466.

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.

Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H. Int J Mol Sci. 2020 Apr 21;21(8):2907. doi: 10.3390/ijms21082907.

 Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia.

Aasebø E, Berven FS, Bartaula-Brevik S, Stokowy T, Hovland R, Vaudel M, Døskeland SO, McCormack E, Batth TS, Olsen JV, Bruserud Ø, Selheim F, Hernandez-Valladares M. Cancers (Basel). 2020 Mar 17;12(3):709. doi: 10.3390/cancers12030709.

The Systemic Metabolic Profile Early after Allogeneic Stem Cell Transplantation: Effects of Adequate Energy Support Administered through Enteral Feeding Tube.

Tvedt THA, Skaarud KJ, Tjønnfjord GE, Gedde-Dahl T, Iversen PO, Bruserud Ø. Biol Blood Marrow Transplant. 2020 Feb;26(2):380-391. doi: 10.1016/j.bbmt.2019.10.005. Epub 2019 Oct 14.

 Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes.

Rundgren IM, Ryningen A, Anderson Tvedt TH, Bruserud Ø, Ersvær E. Molecules. 2020 Jan 16;25(2):367. doi: 10.3390/molecules25020367.

Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment.

Hansen BA, Wendelbo Ø, Bruserud Ø, Hemsing AL, Mosevoll KA, Reikvam H. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020009. doi: 10.4084/MJHID.2020.009. eCollection 2020.

Probiotics to manage inflammation in HIV infection.

Reikvam DH, Meyer-Myklestad MH, Trøseid M, Stiksrud B. Curr Opin Infect Dis. 2020 Feb;33(1):34-43. doi: 10.1097/QCO.0000000000000612.

Hyperferritinemi-katarakt-syndrom.

Benneche A, Sandnes M, Bakke Å, Reikvam H. Tidsskr Nor Laegeforen. 2020 Nov 9;140(16). doi: 10.4045/tidsskr.20.0255. Print 2020 Nov 10.

Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.

Grønningsæter IS, Reikvam H, Aasebø E, Bartaula-Brevik S, Tvedt TH, Bruserud Ø, Hatfield KJ. Cells. 2020 May 7;9(5):1155. doi: 10.3390/cells9051155.

Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach.

Reikvam H, Hemsing AL, Smith C. Expert Rev Anticancer Ther. 2020 Oct 25:1-4. doi: 10.1080/14737140.2021.1838901.

COVID-19 and venous thromboembolism - prophylaxis and treatment.

Kvåle R, Azrakhsh NA, Mohn KG, Aanerud M, Guttormsen AB, Reikvam H. Tidsskr Nor Laegeforen. 2020 Jun 17;140(11). doi: 10.4045/tidsskr.20.0440.

Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics.

Reikvam H. Cells. 2020 Jul 12;9(7):1677. doi: 10.3390/cells9071677.

Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report.

Trovik LH, Sandnes M, Blomberg B, Holmaas G, Ahmed AB, Tvedt THA, Vintermyr O, Reikvam H. J Med Case Rep. 2020 Nov 11;14(1):217. doi: 10.1186/s13256-020-02555-x.

Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder.

Bruserud Ø, Wendelbo Ø, Vetti N, Goplen FK, Johansen S, Reikvam H. Clin Pract. 2020 Jun 10;10(2):1214. doi: 10.4081/cp.2020.1214. eCollection 2020 May 19.

Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment.

Vo AK, Kollsete Gjelberg H, Hovland R, Lindstad Brattås MK, Bruserud Ø, Reikvam H. Case Rep Hematol. 2020 Jan 20;2020:1262038. doi: 10.1155/2020/1262038. eCollection 2020.

Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy.

Vo AK, Reikvam H, Midtbø H, Wirsching JL, Bruserud Ø, Wendelbo Ø. Case Rep Anesthesiol. 2020 Oct 15;2020:4219616. doi: 10.1155/2020/4219616. eCollection 2020.

Epiglottitt.

Bruserud Ø, Engesæter IØ, Mjelle KE, Kristensen F, Wendelbo Ø. Tidsskr Nor Laegeforen. 2020 Sep 11;140(13). doi: 10.4045/tidsskr.20.0382. Print 2020 Sep 29.

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.

Hernandez-Valladares M, Bruserud Ø, Selheim F. Int J Mol Sci. 2020 Sep 17;21(18):6830. doi: 10.3390/ijms21186830.

Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience?

Bruserud Ø, Aarstad HH, Tvedt THA. Cancers (Basel). 2020 Jul 19;12(7):1966. doi: 10.3390/cancers12071966.

Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder.

Bruserud Ø, Wendelbo Ø, Vetti N, Goplen FK, Johansen S, Reikvam H. Clin Pract. 2020 Jun 10;10(2):1214. doi: 10.4081/cp.2020.1214. eCollection 2020 May 19.

Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).

Gudbrandsdottir G, Aarstad HH, Bostad L, Hjelle KM, Aarstad HJ, Bruserud Ø, Tvedt THA, Beisland C. Cancer Immunol Immunother. 2020 Jul 3. doi: 10.1007/s00262-020-02655-z. Online ahead of print

A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies.

Rundgren IM, Ersvær E, Ahmed AB, Ryningen A, Bruserud Ø. Medicina (Kaunas). 2020 Jan 18;56(1):36. doi: 10.3390/medicina56010036.

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile.

Aarstad HH, Guðbrandsdottir G, Hjelle KM, Bostad L, Bruserud Ø, Tvedt THA, Beisland C. Cancers (Basel). 2020 Jul 19;12(7):1961. doi: 10.3390/cancers12071961.

The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles.

Aarstad HH, Moe SEE, Bruserud Ø, Lybak S, Aarstad HJ, Tvedt THA. Biomedicines. 2020 Oct 14;8(10):418. doi: 10.3390/biomedicines8100418.

Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy.

Vo AK, Reikvam H, Midtbø H, Wirsching JL, Bruserud Ø, Wendelbo Ø. Case Rep Anesthesiol. 2020 Oct 15;2020:4219616. doi: 10.1155/2020/4219616. eCollection 2020.

Cold agglutinin disease revisited: a multinational, observational study of 232 patients.

Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Blood. 2020 Jul 23;136(4):480-488. doi: 10.1182/blood.2020005674.

Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.

Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi SS, Cheze S, Ghanima W, Tvedt THA, Ebbo M, Terriou L, Bussel JB, Godeau B. Blood. 2020 Aug 19:blood.2020007594. doi: 10.1182/blood.2020007594.

BMC Immunol. 2019 Nov 8;20(1):39. doi: 10.1186/s12865-019-0323-y.

Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients.

Rundgren IM^1,2, Ersvær E¹, Ahmed AB³, Ryningen A¹, Bruserud Ø^4,5.

Cells. 2019 Oct 10;8(10). pii: E1229. doi: 10.3390/cells8101229.

Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.

Grønningsæter IS^1,2, Fredly HK³, Gjertsen BT^4,5, Hatfield KJ^6,7, Bruserud Ø^8,9.

Cancers (Basel). 2019 Jul 11;11(7). pii: E973. doi: 10.3390/cancers11070973.

Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype.

Brenner AK^1,2, Bruserud Ø^3,4.

J Clin Med. 2019 Jul 4;8(7). pii: E970. doi: 10.3390/jcm8070970.

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype.

Reikvam H^1,2, Aasebø E³, Brenner AK⁴, Bartaula-Brevik S³, Grønningsæter IS⁴, Forthun RB⁴, Hovland R^5,6, Bruserud Ø^3,4.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1729-1749. doi: 10.1007/s00432-019-02931-1. Epub 2019 May 20.

Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.

Forthun RB¹, Hellesøy M², Sulen A¹, Kopperud RK¹, Sjøholt G³, Bruserud Ø^2,4, McCormack E^1,2, Gjertsen BT^5,6.

Signal Transduct Target Ther. 2019 Jun 19;4:20. doi: 10.1038/s41392-019-0050-0. eCollection 2019.

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.

Nepstad I¹, Hatfield KJ^1,2, Grønningsæter IS¹, Aasebø E^1,3, Hernandez-Valladares M^1,3, Hagen KM¹, Rye KP¹, Berven FS³, Selheim F³, Reikvam H^1,4, Bruserud Ø^1,4.

Tidsskr Nor Laegeforen. 2019 Apr 26;139(8). doi: 10.4045/tidsskr.18.0775. Print 2019 May 7.

Treatment of acute myeloid leukaemia in elderly patients.

[Article in Norwegian]

Reikvam H, Dalgaard J, Johansen S, Tvedt THA, Bruserud Ø.

Expert Opin Investig Drugs. 2019 Mar 27:1-10. doi: 10.1080/13543784.2019.1597052. [Epub ahead of print]

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Brattås MK¹, Reikvam H², Tvedt THA², Bruserud Ø^2,3.

Curr Med Chem. 2019 Mar 24. doi: 10.2174/0929867326666190325095853. [Epub ahead of print]

Immunosuppression And Immunotargeted Therapy In Acute Myeloid Leukemia - The Potential Use Of Checkpoint Inhibitors In Combination With Other Treatments.

Leufven E¹, Bruserud O².

Mol Cancer Ther. 2019 Mar;18(3):567-578. doi: 10.1158/1535-7163.MCT-17-1234. Epub 2019 Jan 24.

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.

Bjørnstad R^1,2, Aesoy R¹, Bruserud س, Brenner AK³, Giraud F⁴, Dowling TH⁵, Gausdal G⁶, Moreau P⁴, Døskeland SO⁷, Anizon F⁴, Herfindal L⁸.

Expert Rev Hematol. 2019 Feb;12(2):119-128. doi: 10.1080/17474086.2019.1570126. Epub 2019 Jan 28.

Thrombotic complications in adult patients with severe single coagulation factor or platelet defects - an overview.

Skaadel H¹, Bruserud Ø^1,2.

Cancers (Basel). 2019 Jan 10;11(1). pii: E73. doi: 10.3390/cancers11010073.

The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome.

Brenner AK^1,2, Aasebø E^3,4, Hernandez-Valladares M^5,6, Selheim F⁷, Berven F⁸, Grønningsæter IS^9,10, Bartaula-Brevik S¹¹, Bruserud Ø^12,13.

Neoplasia. 2018 Dec;20(12):1175-1186. doi: 10.1016/j.neo.2018.09.007. Epub 2018 Oct 23.

S100 Proteins in Acute Myeloid Leukemia.

Brenner AK¹, Bruserud ز.

Proteomes. 2018 Dec 20;7(1). pii: E1. doi: 10.3390/proteomes7010001.

Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators.

Aasebø E^1,2, Hernandez-Valladares M^3,4, Selheim F⁵, Berven FS⁶, Brenner AK^7,8, Bruserud Ø^9,10

Biomark Res. 2018 Nov 21;6:33. doi: 10.1186/s40364-018-0147-6. eCollection 2018.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Brattås MK¹, Lilleeng K¹, Hovland R², Lægreid IJ³, Vorland M⁴, Leh F⁵, Bruserud Ø^6,7, Gjertsen BT^6,7, Reikvam H^6,7.

J Immunol Methods. 2018 Oct;461:53-62. doi: 10.1016/j.jim.2018.06.003. Epub 2018 Jun 12.

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood.

Rundgren IM¹, Bruserud ز, Ryningen A³, Ersvær E⁴.

Case Rep Hematol. 2018 Sep 23;2018:2045985. doi: 10.1155/2018/2045985. eCollection 2018.

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation.

Reikvam H^1,2, Skavland J¹, Gullaksen SE¹, Hovland R³, Gedde-Dahl T^4,5, Bruserud Ø^1,2, Gjertsen BT^1,2.

Int J Mol Sci. 2018 Sep 22;19(10). pii: E2886. doi: 10.3390/ijms19102886.

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.

Tvedt THA^1,2, Melve GK^3,4, Tsykunova G⁵, Ahmed AB⁶, Brenner AK⁷, Bruserud Ø^8,9.

Cancers (Basel). 2018 Sep 14;10(9). pii: E332. doi: 10.3390/cancers10090332.

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis.

Nepstad I¹, Hatfield KJ^2,3, Tvedt THA⁴, Reikvam H^5,6, Bruserud Ø^7,8.

Vox Sang. 2018 Aug 29. doi: 10.1111/vox.12703. [Epub ahead of print]

Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases.

Wendelbo ع, Opheim EN², Hervig T^1,3, Felli Lunde TH², Bruserud Ø^1,3, Mollnes TE^4,5,6,7,8, Reikvam H^1,3.

Expert Rev Hematol. 2018 Aug 20:1-3. doi: 10.1080/17474086.2018.1511420. [Epub ahead of print]

Immunological heterogeneity of healthy peripheral blood stem cell donors - preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation.

Bruserud Ø^1,2, Melve GK³, Gedde-Dahl T⁴, Tvedt THA².

Oxf Med Case Reports. 2018 Jul 3;2018(7):omy038. doi: 10.1093/omcr/omy038. eCollection 2018 Jul.

Successful eradication of leptomeningeal plasma cell disease.

Bruserud ع, Hansen BA², Vetti N^3,4, Johansen S⁵, Reikvam H^5,6.

J Immunol Methods. 2018 Jun 12. pii: S0022-1759(17)30510-0. doi: 10.1016/j.jim.2018.06.003. [Epub ahead of print]

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood.

Rundgren IM¹, Bruserud ز, Ryningen A³, Ersvær E⁴.

Clin Pract. 2018 Jun 7;8(2):1061. doi: 10.4081/cp.2018.1061. eCollection 2018 Mar 28.

Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies.

Grønningsæter IS^1,2, Ahmed AB², Vetti N^1,3, Johansen S², Bruserud Ø^1,2, Reikvam H^1,2.

Clin Exp Immunol. 2018 Mar 7. doi: 10.1111/cei.13124. [Epub ahead of print]

A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.

Tvedt THA^1,2, Hovland R³, Tsykunova G¹, Ahmed AB¹, Gedde-Dahl T⁴, Bruserud Ø^1,2.

Cytotherapy. 2018 May;20(5):740-754. doi: 10.1016/j.jcyt.2018.02.366. Epub 2018 Mar 22.

The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis.

Melve GK¹, Ersvaer E², Paulsen Rye K³, Bushra Ahmed A⁴, Kristoffersen EK⁵, Hervig T⁵, Reikvam H⁶, Hatfield KJ⁵, Bruserud Ø⁶.

Expert Opin Investig Drugs. 2018 Apr;27(4):377-387. doi: 10.1080/13543784.2018.1459562. Epub 2018 Apr 4.

Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.

Bartaula-Brevik S¹, Lindstad Brattås MK², Tvedt THA^1,3, Reikvam H^1,3, Bruserud Ø^1,3.

Front Immunol. 2018 Apr 6;9:691. doi: 10.3389/fimmu.2018.00691. eCollection 2018.

Inflammatory Mediator Profiles Differ in Sepsis Patients With and Without Bacteremia.

Mosevoll KA^1,2, Skrede S^1,2, Markussen DL², Fanebust HR³, Flaatten HK⁴, Aßmus J⁵, Reikvam H^1,2, Bruserud Ø^1,2.

Case Rep Oncol Med. 2018 Feb 28;2018:7697283. doi: 10.1155/2018/7697283. eCollection 2018.

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients.

Johansen S¹, Kollsete Gjelberg H², Ahmed AB¹, Bruserud Ø^1,3, Reikvam H^1,3.

Front Immunol. 2018 May 2;9:845. doi: 10.3389/fimmu.2018.00845. eCollection 2018.

Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.

Melve GK^1,2, Ersvaer E³, Eide GE^4,5, Kristoffersen EK^1,2, Bruserud Ø^2,6.

Front Med (Lausanne). 2018 May 22;5:147. doi: 10.3389/fmed.2018.00147. eCollection 2018.

Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.

Mosevoll KA¹, Johansen S¹, Wendelbo ع, Nepstad I¹, Bruserud Ø^1,2, Reikvam H^1,2.

Expert Opin Ther Targets. 2018 Jun 11. doi: 10.1080/14728222.2018.1487401. [Epub ahead of print]

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison.

Nepstad I¹, Hatfield KJ^1,2, Aasebø E³, Hernandez-Valladares M³, Brenner AK¹, Bartaula-Brevik S¹, Berven F³, Selheim F³, Skavland J¹, Gjertsen BT¹, Reikvam H^1,4, Bruserud Ø^1,4.

Int J Mol Sci. 2018 Jan 27;19(2). pii: E382. doi: 10.3390/ijms19020382.

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.

Nepstad I¹, Reikvam H², Brenner AK^3,4, Bruserud Ø^5,6, Hatfield KJ^7,8.

Front Immunol. 2018 Jan 24;8:1979. doi: 10.3389/fimmu.2017.01979. eCollection 2017.

Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers.

Reikvam H^1,2, Grønningsæter IS^1,2, Mosevoll KA^1,2, Lindås R¹, Hatfield K², Bruserud Ø^1,2.

Int J Mol Sci. 2018 Jan 19;19(1). pii: E296. doi: 10.3390/ijms19010296.

Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome.

Wangen R^1,2, Aasebø E^3,4, Trentani A⁵, Døskeland SO⁶, Bruserud Ø⁷, Selheim F^8,9, Hernandez-Valladares M^10,11.

Int J Mol Sci. 2018 Jan 15;19(1). pii: E251. doi: 10.3390/ijms19010251.

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.

Johansen S¹, Brenner AK^2,3, Bartaula-Brevik S⁴, Reikvam H^5,6, Bruserud Ø^7,8.

J Proteomics. 2017 Nov 21. pii: S1874-3919(17)30394-9. doi: 10.1016/j.jprot.2017.11.014. [Epub ahead of print]

Phosphoprotein DIGE profiles reflects blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.

Forthun RB¹, Aasebø E², Rasinger JD³, Bedringaas SL¹, Berven F⁴, Selheim F⁴, Bruserud Ø⁵, Gjertsen BT⁶.

Expert Rev Hematol. 2017 Nov 23:1-12. doi: 10.1080/17474086.2018.1407239. [Epub ahead of print]

Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.

Aasebø E^1,2, Bartaula-Brevik S¹, Hernandez-Valladares M^1,2, Bruserud Ø^1,3.

Expert Opin Drug Discov. 2017 Oct;12(10):1053-1065. doi: 10.1080/17460441.2017.1356818. Epub 2017 Jul 27.

Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.

Bruserud Ø^1,2, Aasebø E^1,3, Hernandez-Valladares M^1,3, Tsykunova G², Reikvam H².

J Cancer Res Clin Oncol. 2017 Oct;143(10):1985-1998. doi: 10.1007/s00432-017-2458-7. Epub 2017 Jun 19.

The constitutive protease release by primary human acute myeloid leukemia cells.

Honnemyr M¹, Bruserud Ø^2,3, Brenner AK^1,4.

BMC Cancer. 2017 Sep 6;17(1):630. doi: 10.1186/s12885-017-3620-y.

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.

Reikvam H¹, Hovland R², Forthun RB³, Erdal S², Gjertsen BT³, Fredly H³, Bruserud س.

Expert Rev Proteomics. 2017 Aug;14(8):649-663. doi: 10.1080/14789450.2017.1352474. Epub 2017 Jul 27.

Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.

Hernandez-Valladares M^1,2, Vaudel M^3,4, Selheim F², Berven F², Bruserud ع.

Front Immunol. 2017 Jun 8;8:667. doi: 10.3389/fimmu.2017.00667. eCollection 2017.

Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.

Tvedt THA^1,2, Ersvaer E³, Tveita AA⁴, Bruserud Ø^1,2.

Expert Rev Clin Immunol. 2017 Jun;13(6):553-569. doi: 10.1080/1744666X.2017.1279053. Epub 2017 Jan 17.

Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment.

Grønningsæter IS^1,2, Tsykunova G¹, Lilleeng K¹, Ahmed AB¹, Bruserud Ø^1,2, Reikvam H³.

Leuk Lymphoma. 2017 Jun;58(6):1494-1497. doi: 10.1080/10428194.2016.1243682. Epub 2016 Oct 14.

Rethinking the role of osteopontin in human acute myeloid leukemia.

Brenner AK¹, Aasebø E², Hernandez-Valladares M², Selheim F², Berven F², Bruserud Ø^1,3.

Expert Opin Ther Targets. 2017 Apr;21(4):357-369. doi: 10.1080/14728222.2017.1300255. Epub 2017 Mar 3.

Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.

Brenner AK¹, Tvedt TH¹, Nepstad I¹, Rye KP¹, Hagen KM¹, Reikvam H^1,2, Bruserud Ø^1,2.

Molecules. 2017 Mar 11;22(3). pii: E446. doi: 10.3390/molecules22030446.

CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.

Brenner AK¹, Reikvam H², Rye KP³, Hagen KM⁴, Lavecchia A⁵, Bruserud Ø^6,7.

Expert Opin Investig Drugs. 2017 Mar;26(3):343-355. doi: 10.1080/13543784.2017.1275564. Epub 2016 Dec 28.

Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.

Tvedt TH¹, Nepstad I², Bruserud Ø^1,2.

Front Immunol. 2017 Feb 9;8:106. doi: 10.3389/fimmu.2017.00106. eCollection 2017.

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.

Brenner AK¹, Nepstad I¹, Bruserud ز.

BMC Immunol. 2017 Jan 28;18(1):5. doi: 10.1186/s12865-017-0190-3.

Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome.

Hanevik K^1,2, Kristoffersen E^3,4, Mørch K^3,5, Rye KP³, Sørnes S³, Svärd S⁶, Bruserud س, Langeland N^3,5.

Metabolomics. 2017;13(1):2. Epub 2016 Nov 28.

Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors.

Hatfield KJ¹, Melve GK¹, Bruserud ز.

Curr Pharm Biotechnol. 2016;17(1):52-70.

Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients.

Aasebø E, Forthun RB, Berven F, Selheim F, Hernandez-Valladares M¹.

Oncotarget. 2016 Dec 10. doi: 10.18632/oncotarget.13853. [Epub ahead of print]

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).

Omsland M¹, Bruserud Ø^2,3, Gjertsen BT^1,3, Andresen V¹.

Tidsskr Nor Laegeforen. 2016 Dec 6;136(22):1889-1894. eCollection 2016 Dec.

Myeloproliferative neoplasms and JAK2 mutations.

[Article in English, Norwegian]

Almedal H¹, Vorland M², Aarsand AK³, Grønningsæter IS⁴, Bruserud Ø⁴, Reikvam H⁵.

Cell Death Dis. 2016 Dec 1;7(12):e2497. doi: 10.1038/cddis.2016.392.

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.

Andresen V¹, Erikstein BS¹, Mukherjee H², Sulen A¹, Popa M^3,4, Sørnes S⁵, Reikvam H⁵, Chan KP^2,6, Hovland R⁷, McCormack E^4,5, Bruserud Ø^4,5, Myers AG², Gjertsen BT^1,4.

Metabolomics. 2016;12(1):12. Epub 2015 Nov 16.

The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation.

Reikvam H¹, Hatfield K², Bruserud ع.

Int J Mol Sci. 2016 Nov 1;17(11). pii: E1823.

Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation.

Tvedt TH¹, Lie SA², Reikvam H^3,4, Rye KP⁵, Lindås R⁶, Gedde-Dahl T⁷, Ahmed AB⁸, Bruserud Ø^9,10.

Molecules. 2016 Nov 11;21(11). pii: E1512.

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.

Brenner AK¹, Andersson Tvedt TH^2,3, Bruserud Ø^4,5.

Cancer Immunol Immunother. 2016 Sep;65(9):1135-47. doi: 10.1007/s00262-016-1865-y. Epub 2016 Aug 1.

Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.

Sand K¹, Theorell J², Bruserud Ø^1,3, Bryceson YT^1,2, Kittang AO^4,5.

Proteomes. 2016 Aug 22;4(3). pii: E24. doi: 10.3390/proteomes4030024.

Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia.

Hernandez-Valladares M¹, Aasebø E², Selheim F³, Berven FS⁴, Bruserud Ø⁵.

J Proteomics. 2016 Aug 11;145:214-25. doi: 10.1016/j.jprot.2016.03.049. Epub 2016 Apr 20.

Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows.

Aasebø E¹, Mjaavatten O², Vaudel M³, Farag Y⁴, Selheim F⁵, Berven F⁶, Bruserud Ø⁷, Hernandez-Valladares M⁸.

Int J Mol Sci. 2016 Jul 19;17(7). pii: E1158. doi: 10.3390/ijms17071158.

Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor.

Melve GK^1,2, Ersvaer E³, Akkök ÇA⁴, Ahmed AB⁵, Kristoffersen EK^6,7, Hervig T^8,9, Bruserud Ø^10,11.

Int J Mol Sci. 2016 Jul 5;17(7). pii: E1080. doi: 10.3390/ijms17071080.

The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.

Kittang AO^1,2, Sand K³, Brenner AK⁴, Rye KP⁵, Bruserud Ø^6,7.

Biol Proced Online. 2016 Jun 21;18:13. doi: 10.1186/s12575-016-0043-0. eCollection 2016.

Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients.

Hernandez-Valladares M¹, Aasebø E¹, Mjaavatten O¹, Vaudel M¹, Bruserud ز, Berven F¹, Selheim F¹.

Oncoimmunology. 2015 Jun 24;5(2):e1062208. eCollection 2016 Feb.

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome.

Kittang AO¹, Kordasti S², Sand KE³, Costantini B², Kramer AM², Perezabellan P², Seidl T², Rye KP³, Hagen KM³, Kulasekararaj A², Bruserud س, Mufti GJ².

Front Immunol. 2016 May 25;7:205. doi: 10.3389/fimmu.2016.00205. eCollection 2016.

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators.

Brenner AK¹, Reikvam H², Bruserud س.

Eur J Haematol. 2016 Mar;96(3):211-21. doi: 10.1111/ejh.12690. Epub 2015 Nov 26.

Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?

Hauge M¹, Bruserud Ø^1,2, Hatfield KJ¹.

Cytotherapy. 2016 Feb;18(2):172-85. doi: 10.1016/j.jcyt.2015.11.010.

Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.

Kallekleiv M¹, Larun L², Bruserud س, Hatfield KJ⁴.

Oncotarget. 2016 Jan 23. doi: 10.18632/oncotarget.6991. [Epub ahead of print]

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.

Leitch C^1,2, Osdal T¹, Andresen V^1,2, Molland M¹, Kristiansen S¹, Nguyen XN¹, Bruserud Ø^1,3, Gjertsen BT^1,2,3, McCormack E^1,3.

Curr Pharm Biotechnol. 2016;17(1):6-19.

The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia.

Forthun RB¹, Hinrichs C, Dowling TH, Bruserud Ø, Selheim F.

Curr Pharm Biotechnol. 2016;17(1):92-104.

Nutrition in Allogeneic Stem Cell Transplantion--Clinical Guidelines and Immunobiological Aspects.

Tvedt TH, Reikvam H, Bruserud ع.

Cytotherapy. 2016 Feb;18(2):172-85. doi: 10.1016/j.jcyt.2015.11.010.

Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.

Kallekleiv M¹, Larun L², Bruserud س, Hatfield KJ⁴.

Oncotarget. 2016 Jan 23. doi: 10.18632/oncotarget.6991. [Epub ahead of print]

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.

Leitch C^1,2, Osdal T¹, Andresen V^1,2, Molland M¹, Kristiansen S¹, Nguyen XN¹, Bruserud Ø^1,3, Gjertsen BT^1,2,3, McCormack E^1,3.

Dis Markers. 2015;2015:943430. doi: 10.1155/2015/943430. Epub 2015 Nov 2.

Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome.

Reikvam H¹, Grønningsæter IS², Ahmed AB², Hatfield K², Bruserud ع.

Eur J Haematol. 2015 Oct 14. doi: 10.1111/ejh.12690. [Epub ahead of print]

Targeting of cell metabolism in human acute myeloid leukemia - more than targeting of IDH mutations and PI3K-AKT-mTOR signaling?

Hauge M¹, Bruserud Ø^1,2, Hatfield KJ¹.

Curr Pharm Biotechnol. 2015 Sep 30. [Epub ahead of print]

NUTRITION IN ALLOGENEIC STEM CELL TRANSPLANTION - CLINICAL GUIDELINES AND IMMUNOBIOLOGICAL ASPECTS.

Tvedt TH, Reikvam H, Bruserud ع.

Stem Cell Res. 2015 Sep 25;15(3):530-541. doi: 10.1016/j.scr.2015.09.008. [Epub ahead of print]

The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells.

Reikvam H¹, Brenner AK², Hagen KM², Liseth K³, Skrede S⁴, Hatfield KJ², Bruserud Ø⁵.

Curr Pharm Biotechnol. 2015 Sep 7. [Epub ahead of print]

The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia.

Forthun RB¹, Hinrichs C, Dowling TH, Bruserud O, Selheim F.

Thromb Res. 2015 Jul;136(1):30-9. doi: 10.1016/j.thromres.2015.04.002. Epub 2015 Apr 11.

Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis.

Mosevoll KA¹, Lindås R², Tvedt TH², Bruserud س, Reikvam H⁴.

Blood Coagul Fibrinolysis. 2015 Jun;26(4):469-72. doi: 10.1097/MBC.0000000000000255.

A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura.

Jonsson MK¹, Hammenfors D, Oppegaard O, Bruserud Ø, Kittang AO.

Cell Rep. 2015 Jun 9;11(9):1446-57. doi: 10.1016/j.celrep.2015.04.063. Epub 2015 May 21.

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Sujobert P¹, Poulain L¹, Paubelle E², Zylbersztejn F², Grenier A¹, Lambert M¹, Townsend EC³, Brusq JM⁴, Nicodeme E⁴, Decrooqc J², Nepstad I⁵, Green AS¹, Mondesir J¹, Hospital MA¹, Jacque N¹, Christodoulou A³, Desouza TA³, Hermine O², Foretz M⁶, Viollet B⁶, Lacombe C¹, Mayeux P¹, Weinstock DM³, Moura IC², Bouscary D¹, Tamburini J⁷.

Expert Rev Hematol. 2015 Jun;8(3):299-313. doi: 10.1586/17474086.2015.1032935. Epub 2015 Apr 3.

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.

Reikvam H¹, Hauge M, Brenner AK, Hatfield KJ, Bruserud Ø.

Expert Rev Hematol. 2015 Jun;8(3):315-27. doi: 10.1586/17474086.2015.1036025. Epub 2015 Apr 22.

Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.

Reikvam H¹, Hoang TT, Bruserud Ø.

BMC Pharmacol Toxicol. 2015 May 2;16:12. doi: 10.1186/s40360-015-0012-2.

Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.

Ersvaer E^1,2, Brenner AK³, Vetås K⁴, Reikvam H⁵, Bruserud Ø^6,7.

J Immunol Methods. 2015 Mar;418:19-28. doi: 10.1016/j.jim.2015.01.006. Epub 2015 Jan 28.

The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers--a comparative study of serum versus plasma samples.

Tvedt TH¹, Rye KP², Reikvam H³, Brenner AK³, Bruserud Ø⁴.

Int J Mol Med. 2015 Mar;35(3):645-52. doi: 10.3892/ijmm.2014.2045. Epub 2014 Dec 19.

Connexin expression in human acute myeloid leukemia cells: identification of patient subsets based on protein and global gene expression profiles.

Reikvam H¹, Ryningen A¹, Sæterdal LR², Nepstad I¹, Foss B², Bruserud ع.

Oncotarget. 2015 Feb 20;6(5):2794-811.

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.

Bruserud Ø^1,2, Reikvam H^1,2, Fredly H^1,2, Skavland J², Hagen KM¹, van Hoang TT¹, Brenner AK¹, Kadi A^3,4,5, Astori A^3,4,5, Gjertsen BT^1,2, Pendino F^6,3,4,5.

Expert Rev Hematol. 2015 Feb;8(1):29-41. doi: 10.1586/17474086.2015.971005. Epub 2014 Nov 6.

STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.

Bruserud ع, Nepstad I, Hauge M, Hatfield KJ, Reikvam H

J Immunol. 2014 Dec 15;193(12):6192-206. doi: 10.4049/jimmunol.1400859. Epub 2014 Nov 7.

NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.

Gras Navarro A¹, Kmiecik J¹, Leiss L², Zelkowski M¹, Engelsen A¹, Bruserud س, Zimmer J⁴, Enger Pز, Chekenya M⁵.

Molecules. 2014 Nov 12;19(11):18414-47. doi: 10.3390/molecules191118414.

Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.

Brenner AK¹, Reikvam H¹, Lavecchia A², Bruserud س.

J Transplant. 2014;2014:404096. doi: 10.1155/2014/404096. Epub 2014 Oct 8.

Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation.

Lindås R¹, Tvedt TH¹, Hatfield KJ², Reikvam H¹, Bruserud O³.

Cell Stem Cell. 2014 Oct 2;15(4):431-46. doi: 10.1016/j.stem.2014.08.001.

SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.

Li L1, Osdal T2, Ho Y1, Chun S1, McDonald T1, Agarwal P1, Lin A1, Chu S1, Qi J1, Li L1, Hsieh YT1, Dos Santos C1, Yuan H3, Ha TQ2, Popa M4, Hovland R5, Bruserud O6, Gjertsen BT6, Kuo YH1, Chen W3, Lain S7, McCormack E8, Bhatia R9.

Springerplus. 2014 Sep 30;3:571. doi: 10.1186/2193-1801-3-571. eCollection 2014.

Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis.

Mosevoll KA¹, Lindås R², Wendelbo O³, Bruserud O⁴, Reikvam H².

Expert Opin Ther Targets. 2014 Sep 9:1-15. [Epub ahead of print]

Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells.

Hatfield KJ, Reikvam H, Bruserud O.

Proteomics. 2014 Sep;14(17-18):1971-6. doi: 10.1002/pmic.201300448. Epub 2014 Aug 8.

Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.

Aasebø E, Vaudel M, Mjaavatten O, Gausdal G, Van der Burgh A, Gjertsen BT, Døskeland SO, Bruserud O, Berven FS, Selheim F.

Cancer Immunol Immunother. 2014 Aug;63(8):757-77. doi: 10.1007/s00262-014-1578-z. Epub 2014 Jul 5.

Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies.

Bruserud Ø, Tvedt TH, Paulsen PQ, Ahmed AB, Gedde-Dahl T, Tjønnfjord GE, Slåstad H, Heldal D, Reikvam H.

Expert Opin Ther Targets. 2014 Aug;18(8):929-44. doi: 10.1517/14728222.2014.924925. Epub 2014 Jun 24.

Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?

Reikvam H, Brenner AK, Nepstad I, Sulen A, Bruserud Ø.

Oncoscience. 2014 Aug 6;1(8):529-39. eCollection 2014.

Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells.

Hampson P¹, Wang K², Ersvær E³, McCormack E³, Schüler J⁴, Fiebig HH⁴, Gjertsen BT³, Bruserud س, Lord JM¹.

Tidsskrift for den Norske laegeforening 2014 May 27;134:1052-5. Norwegian.

Akutt promyelocyttleukemi. [Article in Norwegian]
Reikvam H, Hovland R, Bruserud O.

Tidsskr Nor Laegeforen. 2014 May 27;134(10):1058-61. doi: 10.4045/tidsskr.13.0817. eCollection 2014.

[A man in his 80s with muscle stiffness and skin bleeding].  [Article in Norwegian]

Tvedt TH, Holme PA, Bruserud Ø.

Mol Cancer. 2014 May 21;13:116. doi: 10.1186/1476-4598-13-116.

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.

Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT.

Leukemia. 2014 Feb 27. doi: 10.1038/leu.2014.89. [Epub ahead of print]

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagsrtöm S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA.

Leuk Res Treatment. 2014;2014:143479. doi: 10.1155/2014/143479. Epub 2014 Jan 8.

In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.

Kvestad H, Evensen L, Lorens JB, Bruserud O, Hatfield KJ.

Br J Haematol. 2014 Jan;164(2):200-11. doi: 10.1111/bjh.12611. Epub 2013 Oct 23.

Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.

Reikvam H, Tamburini J, Skrede S, Holdhus R, Poulain L, Ersvaer E, Hatfield KJ, Bruserud O.

Blood Transfus. 2013 Oct 24:1-6. doi: 10.2450/2013.0303-12. [Epub ahead of print]

Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation.

Nepstad I, Reikvam H, Strandenes G, Hess JR, Apelseth TO, Hervig TA.

Expert Opin Investig Drugs. 2013 Nov;22(11):1365-70. doi: 10.1517/13543784.2013.841137. Epub 2013 Oct 7.

Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity.

Reikvam H, Nepstad I, Tamburini J.

Cell Prolif. 2013 Oct;46(5):554-62. doi: 10.1111/cpr.12057.

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.

Reikvam H, Øyan AM, Kalland KH, Hovland R, Hatfield KJ, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Jun;4(6):830-43.

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.

Reikvam H, Nepstad I, Bruserud Ø, Hatfield KJ.

Transfus Med. 2013 Dec;23(6):397-406. doi: 10.1111/tme.12067. Epub 2013 Aug 6.

Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia.

Bruserud O, Liseth K, Stamnesfet S, Cacic DL, Melve G, Kristoffersen E, Hervig T, Reikvam H.

Clin Epigenetics. 2013 Aug 1;5(1):13. doi: 10.1186/1868-7083-5-13.

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.

Fredly H, Ersvær E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O.

Clin Epigenetics. 2013 Jul 30;5(1):12. doi: 10.1186/1868-7083-5-12.

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.

Fredly H, Gjertsen BT, Bruserud O.

BMC Pharmacol Toxicol. 2013 Jul 11;14:35. doi: 10.1186/2050-6511-14-35.

Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine.

Bredholt T, Ersvær E, Erikstein BS, Sulen A, Reikvam H, Aarstad HJ, Johannessen AC, Vintermyr OK, Bruserud Ø, Gjertsen BT.

Cytotherapy. 2013 Apr 24. pii: S1465-3249(13)00409-X. doi: 10.1016/j.jcyt.2013.02.008. [Epub ahead of print]

Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma.

Mosevoll KA, Akkök CA, Hervig T, Melve GK, Bruserud O, Reikvam H.

Expert Opin Investig Drugs. 2013 May;22(5):551-63. doi: 10.1517/13543784.2013.791280.

Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.

Reikvam H, Nepstad I, Sulen A, Gjertsen BT, Hatfield KJ, Bruserud Ø.

Oncoimmunology. 2013 Feb 1;2(2):e23138.

Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.

Sand KE, Rye KP, Mannsåker B, Bruserud O, Kittang AO.

Cell Death Dis. 2013 Feb 28;4:e516. doi: 10.1038/cddis.2013.39.

Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.

Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO.

Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555. Epub 2012 Dec 12.

Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.

McCormack E, Mujić M, Osdal T, Bruserud Ø, Gjertsen BT.

Oncoimmunology. 2013 Feb 1;2(2):e23138.

Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.

Sand KE, Rye KP, Mannsåker B, Bruserud O, Kittang AO.

Toxins (Basel). 2013 Feb 18;5(2):336-62. doi: 10.3390/toxins5020336.

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation.

Reikvam H, Fredly H, Kittang AO, Bruserud O.

Mar Drugs. 2013 Jan 30;11(2):332-49. doi: 10.3390/md11020332.

Iodinin (1,6-Dihydroxyphenazine 5,10-Dioxide) from Streptosporangium sp. Induces Apoptosis Selectively in Myeloid Leukemia Cell Lines and Patient Cells.

Myhren LE, Nygaard G, Gausdal G, Sletta H, Teigen K, Degnes KF, Zahlsen K, Brunsvik A, Bruserud O, Døskeland SO, Selheim F, Herfindal L.

Curr Cancer Drug Targets. 2013 Jan;13(1):30-47.

Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?

Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E, Gjertsen BT, Bruserud Ø.

Eur Cytokine Netw. 2012 Nov 1;23(4):140-53. doi: 10.1684/ecn.2012.0322.

The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation.

Reikvam H, Hatfield KJ, Fredly H, Nepstad I, Mosevoll KA, Bruserud O.

Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555. Epub 2012 Dec 12.

Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.

McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT.

Bone Marrow Res. 2012;2012:329061. doi: 10.1155/2012/329061. Epub 2012 Oct 2.

Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.

Ryningen A, Reikvam H, Nepstad I, Paulsen Rye K, Bruserud O.

Cancer Chemother Pharmacol. 2012 Oct 6. [Epub ahead of print]

High-dose etoposide in allogeneic stem cell transplantation.

Bruserud O, Reikvam H, Kittang AO, Ahmed AB, Tvedt TH, Sjo M, Hatfield KJ.

Eur J Haematol. 2012 Oct 9. doi: 10.1111/ejh.12016. [Epub ahead of print]

Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks.

Hatfield KJ, Evensen L, Reikvam H, Lorens JB, Bruserud O.

Curr Cancer Drug Targets. 2012 Aug 2. [Epub ahead of print]

Targeted Anti-Leukemic Therapy as Disease-Stabilizing Treatment for Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will It Be Possible To Combine These Strategies with Retransplantation or Donor Lymphocyte Infusions?

Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E, Gjertsen BT, Bruserud O.

Blood. 2012 Jul 26;120(4):847-57. Epub 2012 Jun 12.

The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.

Lång E, Grudic A, Pankiv S, Bruserud O, Simonsen A, Bjerkvig R, Bjørås M, Bøe SO.

Expert Opin Investig Drugs. 2012 May;21(5):587-603. Epub 2012 Mar 17.

Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia?

Tsykunova G, Reikvam H, Ahmed AB, Nepstad I, Gjertsen BT, Bruserud O.

Leukemia. 2012 Apr;26(4):563-71. doi: 10.1038/leu.2011.314. Epub 2011 Nov 11.

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.

Reikvam H, Tiu RV.

Am J Hematol. 2012 Apr;87(4):368-76. doi: 10.1002/ajh.23116. Epub 2012 Feb 28.

Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.

Fredly H, Reikvam H, Gjertsen BT, Bruserud O.

Br J Haematol. 2012 Feb;156(4):468-80. doi: 10.1111/j.1365-2141.2011.08960.x. Epub 2011 Dec 13.

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.

Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT, Petersen K, Bruserud O.

Leukemia. 2012 May;26(5):910-7. doi: 10.1038/leu.2011.315. Epub 2011 Nov 8.

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.

McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT.

Biol Blood Marrow Transplant. 2012 Feb;18(2):190-9. doi: 10.1016/j.bbmt.2011.10.007. Epub 2011 Oct 20.

The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications.

Reikvam H, Mosevoll KA, Melve GK, Günther CC, Sjo M, Bentsen PT, Bruserud Ø.

Leukemia. 2012 Mar;26(3):557-9. doi: 10.1038/leu.2011.243. Epub 2011 Sep 9.

The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status.

Tsykunova G, Reikvam H, Hovland R, Bruserud Ø.

Oncogene. 2012 Mar 22;31(12):1533-45. doi: 10.1038/onc.2011.348. Epub 2011 Aug 22.

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.

Ånensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon JC, Hovland R, Taskén K, Knappskog S, Lønning PE, Bruserud Ø, Gjertsen BT.

Leukemia. 2012 Apr;26(4):563-71. doi: 10.1038/leu.2011.314. Epub 2011 Nov 11.

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.

Reikvam H, Tiu RV.

Hematology. 2011 Nov;16(6):351-6.

Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia.

Hatfield KJ, Lassalle P, Leiva RA, Lindås R, Wendelboe Ø, Bruserud Ø.

Bone Marrow Res. 2011;2011:570796. Epub 2010 Oct 4.

Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies.

Ersvaer E, Hatfield KJ, Reikvam H, Bruserud O.

Biol Blood Marrow Transplant. 2012 Feb;18(2):190-9. Epub 2011 Oct 20.

The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications.

Reikvam H, Mosevoll KA, Melve GK, Günther CC, Sjo M, Bentsen PT, Bruserud Ø.

J Infect Dis. 2011 Dec;204(11):1779-86. Epub 2011 Oct 11.

Human cellular immune response against Giardia lamblia 5 years after acute giardiasis.

Hanevik K, Kristoffersen E, Svard S, Bruserud O, Ringqvist E, Sørnes S, Langeland N.

Cancer Immunol Immunother. 2011 Dec;60(12):1669-81. Epub 2011 Oct 12.

Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?

Ersvær E, Melve GK, Bruserud O.

Expert Rev Hematol. 2011 Oct;4(5):563-76.

The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?

Melve GK, Ersvssr E, Kittang AO, Bruserud O.

Cytotherapy. 2011 Nov;13(10):1259-68. doi: 10.3109/14653249.2011.605117. Epub 2011 Sep 12.

Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma.

Akkök CA, Hervig T, Stamnesfet S, Nesthus I, Melve GK, Lassalle P, Bruserud O.

Leuk Res. 2011 Sep;35(9):1156-8. Epub 2011 Jul 30.

Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.

Bruserud Ø, Hatfield KJ, Reikvam H.

J Biomed Biotechnol. 2011;2011:104631. Epub 2011 May 3.

Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø.

Cytotherapy. 2011 Sep;13(8):1013-24. Epub 2011 Apr 20.

Is there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts?

Akkök CA, Liseth K, Melve GK, Ersvaer E, Hervig T, Bruserud Ø.

Oncol Rep. 2011 Jun;25(6):1549-56. doi: 10.3892/or.2011.1229. Epub 2011 Mar 22.

Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.

Fredly H, Ersvær E, Gjertsen BT, Bruserud O.

Eur Cytokine Netw. 2011 Mar;22(1):52-62.

A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia.

Apelseth TO, Hervig T, Wentzel-Larsen T, Petersen K, Reikvam H, Bruserud Ø.

Blood Rev. 2011 May;25(3):113-22. Epub 2011 Feb 12.

Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia.

Apelseth TO, Hervig T, Bruserud O.

Blood Cancer J. 2011 Feb;1(2):e4. doi: 10.1038/bcj.2011.2. Epub 2011 Feb 11.

Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia.

Skavland J, Jørgensen KM, Hadziavdic K, Hovland R, Jonassen I, Bruserud O, Gjertsen BT.

J Proteomics. 2011 Mar 1;74(3):269-81. Epub 2010 Nov 12.

Untangling the intracellular signalling network in cancer--a strategy for data integration in acute myeloid leukaemia.

Jørgensen KM, Hjelle SM, Øye OK, Puntervoll P, Reikvam H, Skavland J, Anderssen E, Bruserud Ø, Gjertsen BT.

Curr Med Chem. 2010;17(36):4448-61.

The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia.

Hatfield KJ, Reikvam H, Bruserud Ø.

Curr Top Microbiol Immunol. 2010;341:v-vi.

The chemokine system in experimental and clinical hematology. Preface.

Bruserud Ø.

Expert Opin Ther Targets. 2010 Nov;14(11):1139-42.

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.

Bruserud Ø, Reikvam H.

Hematology. 2010 Oct;15(5):338-43.

Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.

Fredly H, Stapnes Bjørnsen C, Gjertsen BT, Bruserud Ø.

Blood. 2010 Sep 2;116(9):1389-90.

Antivascular combo therapy: up-and-coming.

Bruserud O, Hatfield K.

Eur Cytokine Netw. 2010 Sep;21(3):154-64. Epub 2010 Aug 20.

Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells.

Hatfield KJ, Bedringsaas SL, Ryningen A, Gjertsen BT, Bruserud O.

Leuk Res. 2010 Nov;34(11):1422-3. Epub 2010 Jul 16.

Heat shock protein 90 (HSP90) inhibition--from experimental to clinical studies.

Bruserud Ø, Reikvam H.

J Biomed Biotechnol. 2010;2010:692097. Epub 2010 Jun 2.

Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Liseth K, Ersvaer E, Hervig T, Bruserud Ø.

BMC Immunol. 2010 Jul 9;11:38.

Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.

Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud Ø.

Genome Med. 2010 Jun 29;2(6):41.

Clinical proteomics of myeloid leukemia.

Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjøholt G, Bruserud O, Gjertsen BT.

Nutr Cancer. 2010;62(5):574-83.

Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia.

McCormack E, Skavland J, Mujic M, Bruserud Ø, Gjertsen BT.

Transfus Apher Sci. 2010 Aug;43(1):33-6. Epub 2010 Jun 16.

Minor diurnal and activity-induced variations in daytime peripheral blood platelet counts do not have any major impact on platelet yield by platelet apheresis.

Akkök CA, Hervig T, Bjørsvik S, Underdal MO, Skoug CF, Ersvaer E, Bruserud Ø.

Apoptosis. 2010 Aug;15(8):946-55.

Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).

Hampson P, Wang K, Milverton L, Ersvaer E, Bruserud O, Lord JM.

Curr Top Microbiol Immunol. 2010;341:149-72.

The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications.

Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud Ø.

Curr Top Microbiol Immunol. 2010;341:3-12.

The chemokine system in experimental and clinical hematology.

Bruserud Ø, Kittang AO.

Eur Cytokine Netw. 2010 Mar;21(1):40-9.

Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease.

Liseth K, Sjo M, Paulsen K, Bruserud Ø, Ersvaer E.

Expert Opin Investig Drugs. 2010 Feb;19(2):169-83.

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud Ø.

Toxins (Basel). 2010 Jan;2(1):174-94. Epub 2010 Jan 22.

The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity.

Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, Bruserud O.

Transfusion. 2010 Apr;50(4):766-75. Epub 2009 Dec 18.

Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods.

Apelseth TO, Bruserud O, Wentzel-Larsen T, Hervig T.

Eur J Haematol. 2010 Mar;84(3):239-51. Epub 2009 Nov 17.

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O.

Biochim Biophys Acta. 2010 Jan;1798(1):1-8. Epub 2009 Oct 31.

Connexin-based signaling in acute myelogenous leukemia (AML).

Foss B, Tronstad KJ, Bruserud Ø.

Crit Rev Oncog. 2009;15(1-2):1-41.

Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.

Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud Ø.

J BUON. 2009 Sep;14 Suppl 1:S131-40.

The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia.

Olsnes AM, Hatfield KJ, Bruserud Ø.

Crit Rev Oncog. 2009;15(1):1-36.

Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia.

Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud O.

Cytotherapy. 2009;11(6):749-60.

Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators.

Akkök CA, Liseth K, Hervig T, Ryningen A, Bruserud Ø, Ersvaer E.

Curr Cancer Drug Targets. 2009 Sep;9(6):761-76.

Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

Reikvam H, Ersvaer E, Bruserud O.

Hematology. 2009 Aug;14(4):224-6. doi: 10.1179/102453309X439782.

Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report.

Bruserud Ø, Håvardstein K.

Transfusion. 2009 Aug;49(8):1709-19.

Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells.

Liseth K, Ersvær E, Abrahamsen JF, Nesthus I, Ryningen A, Bruserud Ø.

Br J Haematol. 2009 Jun;145(6):761-74. Epub 2009 Apr 20.

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.

Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, Gjertsen BT, Kristoffersen EK, Bruserud Ø.

Stem Cells Dev. 2009 Jul-Aug;18(6):807-12.

Connexins are active participants of hematopoietic stem cell regulation.

Foss B, Hervig T, Bruserud O.

Expert Opin Investig Drugs. 2009 Apr;18(4):433-55.

Targeted therapy in acute myeloid leukaemia: current status and future directions.

Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø.

BMC Cancer. 2009 Mar 5;9:77.

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.

Øyan AM, Anensen N, Bø TH, Stordrange L, Jonassen I, Bruserud Ø, Kalland KH, Gjertsen BT.

Tidsskr Nor Laegeforen. 2009 Feb 26;129(5):416-9.

[Granulocyte transfusion]. [Article in Norwegian]

Reikvam H, Blom US, Kristoffersen E, Liseth K, Bruserud O, Hervig T.

Br J Haematol. 2009 Jan;144(1):53-68. Epub 2008 Oct 30.

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.

Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø.

Leuk Res. 2009 Jun;33(6):779-87. Epub 2008 Nov 12.

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.

Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O.

Transfusion. 2009 Feb;49(2):354-61. Epub 2008 Oct 28.

Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.

Akkök CA, Holte MR, Tangen JM, Ostenstad B, Bruserud O.

Curr Cancer Drug Targets. 2008 Dec;8(8):666-75.

Anticancer immunotherapy in combination with proapoptotic therapy.

Bruserud Ø, Ersvaer E, Olsnes A, Gjertsen BT.

Hematology. 2008 Dec;13(6):329-32.

Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors.

Olsnes AM, Ersvaer E, Ryningen A, Bruserud O.

Expert Opin Investig Drugs. 2008 Nov;17(11):1623-33.

In vivo biological effects of ATRA in the treatment of AML.

Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O.

J Interferon Cytokine Res. 2008 May;28(5):297-310.

In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.

Olsnes AM, Ryningen A, Ersvaer E, Bruserud Ø.

Transfusion. 2008 May;48(5):877-83. Epub 2008 Feb 21.

Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.

Akkök CA, Liseth K, Nesthus I, Løkeland T, Tefre K, Bruserud O, Abrahamsen JF.

Platelets. 2008 Mar;19(2):155-9.

Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro.

Foss B, Bruserud O, Hervig T.

Oncogene. 2008 Jun 19;27(27):3765-79. doi: 10.1038/onc.2008.16. Epub 2008 Feb 11.

Review: genetic models of acute myeloid leukaemia.

McCormack E, Bruserud O, Gjertsen BT.

Thromb Haemost. 2008 Jan;99(1):27-37.

Platelet functions and clinical effects in acute myelogenous leukemia.

Foss B, Bruserud O.

Blood. 2008 Mar 1;111(5):2866-77. Epub 2008 Jan 8.

Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death.

Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, Krakstad C, Bruserud Ø, Gevaert K, Vandekerckhove J, Døskeland SO.

Leukemia. 2008 Feb;22(2):287-93. Epub 2007 Oct 18.

Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels.

Hatfield KJ, Hovland R, Øyan AM, Kalland KH, Ryningen A, Gjertsen BT, Bruserud Ø.

Curr Pharm Biotechnol. 2007 Dec;8(6):401-11.

Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects.

Ryningen A, Bruserud Ø.

Curr Pharm Biotechnol. 2007 Dec;8(6):344-54.

Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in acute myeloid leukemia.

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Tore Gjertsen B, Bruserud O, Kalland KH.

Curr Pharm Biotechnol. 2007 Dec;8(6):318-9.

Introduction: RNA and the treatment of human cancer.

Bruserud O.

Int J Oncol. 2007 Dec;31(6):1529-38.

Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.

Stapnes C, Ryningen A, Hatfield K, Øyan AM, Eide GE, Corbascio M, Kalland KH, Gjertsen BT, Bruserud Ø.

Expert Opin Ther Targets. 2007 Aug;11(8):1055-69.

Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.

Hagland H, Nikolaisen J, Hodneland LI, Gjertsen BT, Bruserud Ø, Tronstad KJ.

Eur J Haematol. 2007 Sep;79(3):210-25. Epub 2007 Jul 26.

Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.

Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O.

Hematology. 2007 Jun;12(3):199-207.

Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.

Ersvaer E, Hampson P, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.

Mol Cancer. 2007 May 11;6:33.

Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.

Wergeland L, Sjøholt G, Haaland I, Hovland R, Bruserud Ø, Gjertsen BT.

Expert Rev Anticancer Ther. 2007 May;7(5):741-51.

Early gene expression of acute myeloid leukemia in response to chemotherapy.

Anensen N, Øyan AM, Huseby S, Kalland KH, Bruserud Ø, Gjertsen BT.

Mol Cancer. 2007 Apr 23;6:31.

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.

Huang TS, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud Ø, Døskeland SO, Lillehaug JR.

Anal Biochem. 2007 Jul 1;366(1):46-58. Epub 2007 Mar 18.

Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.

Petersen K, Oyan AM, Rostad K, Olsen S, Bø TH, Salvesen HB, Gjertsen BT, Bruserud O, Halvorsen OJ, Akslen LA, Steen VM, Jonassen I, Kalland KH.

Leuk Res. 2007 Sep;31(9):1303-13. Epub 2007 Apr 9.

Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.

Ryningen A, Stapnes C, Bruserud Ø.

Transfusion. 2007 Apr;47(4):653-65.

In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.

Apelseth TØ, Bruserud Ø, Wentzel-Larsen T, Bakken AM, Bjørsvik S, Hervig T.

Br J Haematol. 2007 Mar;136(6):814-28.

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

Stapnes C, Døskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O.

Haematologica. 2007 Mar;92(3):332-41.

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.

Bruserud Ø, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, Gjertsen BT.

Cancer Immunol Immunother. 2007 Jun;56(6):913-25. Epub 2006 Nov 8.

T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005.

Ersvaer E, Hampson P, Hatfield K, Ulvestad E, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.

Blood. 2007 Mar 15;109(6):2589-96. Epub 2006 Nov 14.

Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.

Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, Nolan GP, Gjertsen BT.

Cancer Immunol Immunother. 2007 Jan;56(1):13-24. Epub 2006 Apr 13.

Effects of interferon gamma on native human acute myelogenous leukaemia cells.

Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud Ø.

Platelets. 2006 Aug;17(5):296-302.

Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.

Ryningen A, Apelseth T, Hausken T, Bruserud Ø.

Int J Cancer. 2006 Nov 15;119(10):2313-21.

Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts.

Hatfield K, Ryningen A, Corbascio M, Bruserud O.

Clin Cancer Res. 2006 Jul 1;12(13):3985-92.

A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia.

Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT.

Transfusion. 2006 May;46(5):800-10.

Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage.

Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O.

Acta Oncol. 2006;45(3):346-9.

Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia.

Stapnes C, Ryningen A, Gjertsen BT, Bruserud Ø.

Cancer. 2006 Jun 1;106(11):2397-405.

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders.

Cancer Immunol Immunother. 2007 Jan;56(1):13-24. Epub 2006Apr 13.

Effects of interferon gamma on native human acute myelogenous leukaemia cells.

Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud Ø.

BMC Bioinformatics. 2006 Apr 10;7:198.

Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables.

Van Belle W, Anensen N, Haaland I, Bruserud Ø, Høgda KA, Gjertsen BT.

Leuk Res. 2006 Dec;30(12):1531-40. Epub 2006 Apr 5.

Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90.

Ryningen A, Ersvaer E, Øyan AM, Kalland KH, Vintermyr OK, Gjertsen BT, Bruserud Ø.

Int J Oncol. 2006 May;28(5):1065-80.

cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.

Øyan AM, Bø TH, Jonassen I, Gjertsen BT, Bruserud Ø, Kalland KH.

Expert Opin Ther Targets. 2006 Feb;10(1):51-68.

Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.

Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT.

Leukemia. 2006 Apr;20(4):734-6.

Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.

Anensen N, Skavland J, Stapnes C, Ryningen A, Børresen-Dale AL, Gjertsen BT, Bruserud Ø.

Cancer Immunol Immunother. 2006 Jul;55(7):830-40. Epub 2005 Nov 3.

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC).

Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud Ø.

Cancer Immunol Immunother. 2006 Feb;55(2):221-8. Epub 2005 Jul 21.

Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?

Bruserud Ø, Tronstad KJ, McCormack E, Gjertsen BT.

Cancer Immunol Immunother. 2006 Feb;55(2):185-7. Epub 2005 Jul 7.

Immunotherapy in chronic lymphocytic leukemia.

Bruserud Ø, McCormack E, Gjertsen BT.

Scand J Clin Lab Invest. 2005;65(6):505-11.

Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin.

Bruserud O, Grovan F, Lindås R, Blymke Møinichen C, Osterhus KK.

Curr Drug Targets. 2005 Sep;6(6):631-46.

Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.

Sjøholt G, Anensen N, Wergeland L, Mc Cormack E, Bruserud Ø, Gjertsen BT.

Cytotherapy. 2005;7(4):328-33.

The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft.

Liseth K, Abrahamsen JF, Bjørsvik S, Grøttebø K, Bruserud Ø.

Curr Cancer Drug Targets. 2005 Jun;5(4):229-48.

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.

Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø.

J Cancer Res Clin Oncol. 2005 Jun;131(6):377-84. Epub 2005 Mar 18.

In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum.

Bruserud O, Tronstad KJ, Berge R.

Cytometry B Clin Cytom. 2005 Mar;64(1):18-27.

CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Gjertsen BT, Kalland KH, Bruserud O.

Transfusion. 2005 Feb;45(2):248-53.

Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells.

Abrahamsen JF, Stamnesfet S, Liseth K, Hervig T, Bruserud O.

Eur J Haematol. 2005 Jan;74(1):24-34.

Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels.

Glenjen NI, Hatfield K, Bruserud Ø.

Leuk Res. 2005 Feb;29(2):185-96.

In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8.

Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud O.

Cytotherapy. 2004;6(4):356-62.

Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg.

Abrahamsen JF, Wentzel-Larsen T, Bruserud O.

Eur J Haematol. 2004 Nov;73(5):340-50.

Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts.

Bruserud Ø, Wendelbo Ø, Paulsen K.

Int J Cancer. 2004 Oct 10;111(6):858-67.

In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts.

Glenjen N, Ersvaer E, Ryningen A, Bruserud Ø.

Cell. 2004 Jul 23;118(2):217-28.

Single cell profiling of potentiated phospho-protein networks in cancer cells.

Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Gjertsen BT, Nolan GP.

Scand J Immunol. 2004 Jul-Aug;60(1-2):189-98.

Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease.

Ersvaer E, Bertelsen LT, Espenes LC, Bredholt T, Bøe SO, Iversen BM, Bruserud Ø, Ulvestad E, Gjertsen BT.

Cancer Immunol Immunother. 2004 Aug;53(8):740-7. Epub 2004 May 5.

Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.

Wendelbo Ø, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud Ø.

Transfusion. 2004 May;44(5):785-9.

Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide.

Abrahamsen JF, Rusten L, Bakken AM, Bruserud Ø.

Haematologica. 2004 Apr;89(4):391-402.

Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.

Bruserud Ø, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT.

Cancer Immunol Immunother. 2004 Aug;53(8):677-80. Epub 2004 Apr 7.

How should clinical data be included in experimental studies of cancer immunology?

Gjertsen BT, Bruserud Ø.

Leuk Res. 2004 May;28(5):461-8.

Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Wendelbo Ø, Nesthus I, Sjo M, Ernst P, Bruserud Ø.

J Hematother Stem Cell Res. 2003 Oct;12(5):525-35.

Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay.

Wendelbo Ø, Bruserud Ø.

Hematology. 2003 Oct;8(5):313-8.

Characterization of clonogenic progenitors in autologous peripheral blood stem cell grafts: evaluation of a simple in vitro assay suitable for routine clinical use.

Motorin D, Bakken A, Foss Abrahamsen J, Ernst P, Bruserud Ø.

Expert Opin Ther Targets. 2003 Oct;7(5):663-77.

Modified fatty acids and their possible therapeutic targets in malignant diseases.

Tronstad KJ, Berge K, Berge RK, Bruserud Ø.

Eur J Haematol. 2003 Sep;71(3):163-73.

The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status.

Glenjen N, Hovland R, Wergeland L, Wendelbo Ø, Ernst P, Bruserud Ø.

J Hematother Stem Cell Res. 2003 Jun;12(3):351-8.

No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide.

Bakken AM, Bruserud O, Abrahamsen JF.

Eur J Haematol. 2003 Jul;71(1):9-17.

Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts.

Bruserud Ø, Glenjen N, Ryningen A.

Haematologica. 2003 Apr;88(4):416-28.

Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.

Bruserud Ø, Hovland R, Wergeland L, Huang TS, Gjertsen BT.

Cancer Immunol Immunother. 2003 Apr;52(4):215-25. Epub 2003 Feb 15.

Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells.

Bruserud O, Ulvestad E.

Leuk Res. 2003 May;27(5):455-64.

In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines.

Bruserud Ø, Glenjen N, Ryningen A, Ulvestad E.